Pv malaria hospitalized injection

Reading File

Finding Sources

Searching PubMed

"Plasmodium vivax" AND "severe malaria" AND treatment

Reading File

I now have all the information needed to give a thorough, well-sourced answer. Here is the complete clinical guide:

P. vivax Malaria - Hospitalized (Parenteral Treatment)

When to Hospitalize / Use Parenteral Therapy

Patients with P. vivax malaria require hospitalization and parenteral treatment when they present with severe malaria or are unable to take oral medications (vomiting, altered consciousness). Severe malaria criteria include:

Impaired consciousness / coma
Repeated convulsions
Renal failure (creatinine >3 mg/dL)
Jaundice (bilirubin >3 mg/dL)
Severe anaemia (Hb <5 g/dL)
Pulmonary oedema / ARDS
Hypoglycaemia (glucose <40 mg/dL)
Metabolic acidosis
Circulatory collapse / shock (systolic BP <80 mmHg)
Abnormal bleeding / DIC
Haemoglobinuria
Hyperthermia (>106°F / 42°C)
Hyperparasitaemia (>5% parasitised RBCs in low-endemic areas)

(Park's Textbook of Preventive and Social Medicine)

First-Line Parenteral Drug: IV/IM Artesunate

Artesunate is the drug of choice for all patients with severe malaria, including severe P. vivax.

"In large randomized controlled clinical trials, parenteral artesunate reduced severe falciparum malaria mortality rates by 35% in Asian adults and children and by 22.5% in African children compared with quinine treatment. Artesunate therefore is now the drug of choice for all patients with severe malaria everywhere."

Harrison's Principles of Internal Medicine 22E, 2025

Artesunate Dosing (IV or IM)

Timing	Dose
Admission (0 h)	2.4 mg/kg IV or IM
12 hours	2.4 mg/kg
24 hours	2.4 mg/kg
Then once daily	2.4 mg/kg until oral tolerated

Children <20 kg: 3 mg/kg per dose (higher weight-adjusted dose)
Minimum parenteral treatment: 24 hours (even if patient can tolerate oral earlier)
IV artesunate is water-soluble and can also be given IM; it is absorbed rapidly by both routes

(Harrison's 22E; Park's Textbook)

Second-Line Parenteral Options (if Artesunate Unavailable)

Drug	Dose & Route
Artemether (IM, oil-based)	3.2 mg/kg IM loading dose, then 1.6 mg/kg/day IM
Arteether (arteether/artemotil)	150 mg IM daily for 3 days - adults only (NOT in children)
Quinine dihydrochloride (IV infusion)	Loading: 20 mg salt/kg over 4 hours; then 10 mg salt/kg over 2-8 hours every 8 hours

Note: Artemether and arteether are oil-based IM formulations with erratic absorption - they do NOT confer the same survival benefit as artesunate.

Note on Quinine loading dose: Do NOT give the 20 mg/kg loading dose if therapeutic quinine has already been given in the previous 24 hours. Infusion rate must not exceed 5 mg/kg per hour.

(Park's Textbook; Harrison's 22E)

Critical Addition for P. vivax: Radical Cure

P. vivax forms dormant liver hypnozoites that cause relapses. A drug active against the liver stage is mandatory:

Drug	Dose	Notes
Primaquine	0.25-0.5 mg base/kg/day x 14 days	Standard radical cure
Tafenoquine	Single dose (alternative)	Once-daily, single-dose convenience

"Artesunate should be administered with an antimalarial active against the hypnozoite liver stage (for example, primaquine or tafenoquine) in the treatment of severe P. vivax or P. ovale."

Lippincott Illustrated Reviews: Pharmacology

IMPORTANT: Test for G6PD deficiency before giving primaquine or tafenoquine. Both drugs cause haemolysis in G6PD-deficient patients. In G6PD deficiency, weekly low-dose primaquine is used cautiously. Tafenoquine is contraindicated in G6PD deficiency.

Step-Down to Oral Therapy

Once the patient can tolerate oral medications (after minimum 24-48 hours parenteral):

Prior Parenteral Regimen	Step-Down Oral Therapy
After artesunate	Full 3-day course of area-specific ACT + primaquine
After quinine	Oral quinine 10 mg/kg TDS x 7 days + doxycycline 3 mg/kg/day x 7 days (or clindamycin in children <8 yrs / pregnant women)

India-specific ACT regimens (Park's/NVBDCP):

North-East states: ACT-AL (artemether-lumefantrine) for 3 days + primaquine single dose on day 2
Other states: ACT-SP (artesunate + sulfadoxine-pyrimethamine) for 3 days + primaquine single dose on day 2

Special Populations

Population	Modification
Pregnancy	Artesunate derivatives preferred over quinine (quinine worsens hypoglycaemia in pregnancy); primaquine is contraindicated - defer radical cure to post-partum
Children <8 yrs	Avoid doxycycline; use clindamycin instead
G6PD deficiency	Do NOT give standard primaquine; use supervised weekly dosing or withhold
Artemisinin resistance areas	Give parenteral artesunate + quinine together at standard doses

Summary Flow

Severe P. vivax / Unable to take oral
            ↓
IV/IM Artesunate 2.4 mg/kg at 0h, 12h, 24h → then once daily
            ↓ (minimum 24-48 h parenteral)
Switch to oral ACT (3-day course)
            ↓
Add Primaquine (14 days) for radical cure
[Check G6PD before primaquine]

Sources:

Harrison's Principles of Internal Medicine, 22nd Edition (2025), Chapter 231 - Malaria
Park's Textbook of Preventive and Social Medicine - Treatment of Severe Malaria
Lippincott Illustrated Reviews: Pharmacology - Artemisinin section

Recent evidence note: A 2024 Lancet Infectious Diseases systematic review (PMID 37748496) confirmed that higher-dose primaquine regimens reduce P. vivax recurrence risk; a companion review (PMID 37748497) showed dose-dependent haemolysis risk - supporting the importance of G6PD screening before radical cure.

Patient is adult write the prescription for it

Here is a sample inpatient prescription for a hospitalized adult with severe P. vivax malaria:

🏥 INPATIENT PRESCRIPTION

Ward: Medicine / Infectious Disease Diagnosis: Severe Plasmodium vivax Malaria Patient: Adult (assumed ~60 kg for dosing) Date: 18/07/2026

⚠️ BEFORE STARTING

Send peripheral blood smear + RDT
Send G6PD level (before primaquine)
CBC, LFT, RFT, blood glucose, serum electrolytes
Blood culture (to rule out co-infection)
Urine routine + microscopy
IV access secured

Rx — PHASE 1: PARENTERAL (Day 1–2, minimum 24–48 hrs)

1. Inj. Artesunate 2.4 mg/kg IV (= ~144 mg for 60 kg adult) Dissolve in 5 mL sodium bicarbonate diluent provided, then dilute in 50 mL NS/D5W Give as slow IV infusion over 1–2 minutes (or IM if IV not feasible)

Dose	Time
1st dose	At admission (0 h)
2nd dose	At 12 hours
3rd dose	At 24 hours
Subsequent doses	Once daily until oral tolerated

2. Inj. Dextrose 10% in NS 500 mL IV Run at 40–60 mL/hr (maintenance + hypoglycaemia prevention) (Monitor blood glucose every 4 hours — quinine/malaria can cause hypoglycaemia)

3. Tab. Paracetamol 500 mg PO / Inj. Paracetamol 1g IV Every 6–8 hours PRN for fever / temperature >38.5°C

4. Inj. Ondansetron 4 mg IV Every 8 hours PRN for nausea/vomiting

Rx — PHASE 2: ORAL STEP-DOWN (Day 3 onwards, once tolerating orally)

(Switch after minimum 48 hrs parenteral and patient is conscious + tolerating oral)

5. Tab. Artemether + Lumefantrine (AL) 80/480 mg (Co-artem / Lumether — standard adult pack = 24 tablets)

Day	Timing	Dose
Day 1	Hour 0	4 tablets
Day 1	Hour 8	4 tablets
Day 2	Morning	4 tablets
Day 2	Evening	4 tablets
Day 3	Morning	4 tablets
Day 3	Evening	4 tablets

Take with fatty food or full-fat milk (enhances lumefantrine absorption)

6. Tab. Primaquine 15 mg (For radical cure — eliminates liver hypnozoites / prevents relapse) 2 tablets (30 mg) orally once daily × 14 days

⚠️ START ONLY AFTER G6PD result is confirmed NORMAL Primaquine causes severe haemolysis in G6PD-deficient patients. Give with food to reduce GI side effects.

Rx — SUPPORTIVE CARE

Drug	Dose	Route	Frequency
Tab. Folic Acid 5 mg	1 tab	PO	Once daily
Tab. Ferrous Sulfate 200 mg	1 tab	PO	Twice daily (for anaemia)
Cap. Vitamin B-complex	1 cap	PO	Once daily

MONITORING ORDERS

Temperature, Pulse, BP, SpO₂ — every 4 hours
Blood glucose — every 4 hours (especially if on IV fluids)
Repeat blood smear at 48 h and 72 h to confirm parasite clearance
Urine output chart (watch for oliguria / haemoglobinuria)
Daily CBC during admission
LFT at Day 3 (artesunate can elevate transaminases)

CAUTIONS / CONTRAINDICATIONS

Situation	Action
G6PD deficiency confirmed	Withhold primaquine; consult specialist
Pregnancy	Withhold primaquine until post-partum; artesunate is safe in all trimesters
Impaired consciousness	Keep NBM; use nasogastric tube for medications if needed
Convulsions	Inj. Diazepam 10 mg IV slow push PRN; maintain airway
Renal failure	Artesunate dose unchanged; adjust fluids carefully

DISCHARGE CRITERIA

Afebrile for >48 hours
Tolerating full oral diet and medications
Parasitaemia cleared on smear
No danger signs
Primaquine course to be completed at home (14-day course)

Note: This is a sample/educational prescription template. Actual dosing must be adjusted for the patient's measured weight, renal/hepatic status, G6PD result, local drug availability, and treating physician's clinical judgement. In India, follow NVBDCP / National Drug Policy on Malaria guidelines.

Should i add ceftriaxone also

Finding Sources

Searching PubMed

"malaria" AND "bacterial coinfection" AND "empirical antibiotic"

Finding Sources

Searching PubMed

"malaria" AND "bacteremia" AND "coinfection" AND antibiotic

Reading File

Now I have exactly what I need. Here is the clear, evidence-based answer:

Should You Add Ceftriaxone?

Short answer: Not routinely. Only add it if there is clinical or microbiological evidence of bacterial co-infection.

What the Evidence Says

Harrison's (2025) states directly:

"Approximately 6% of children diagnosed with severe malaria have concomitant bacteremia. In adults, the proportion is lower (<1%), except in those with very high parasite counts (>20% parasitaemia). In endemic areas, Salmonella spp. bacteremia has been associated specifically with P. falciparum infections."

So bacterial co-infection in adults with P. vivax is uncommon - blanket empirical antibiotics are not standard practice.

When to ADD Ceftriaxone (Justified)

Clinical Situation	Rationale
Fever not responding after 48 hrs of artesunate	Suggests co-existing bacterial source
Features of septic shock (hypotension, cold peripheries, high lactate)	Bacterial sepsis likely co-existing
Positive blood culture / procalcitonin very high	Confirmed bacteremia
Aspiration pneumonia (unconscious patient, post-convulsion)	Gram-negative / anaerobe cover needed
Catheter-associated UTI (unconscious >3 days)	Common nosocomial co-infection
Concurrent typhoid (Salmonella endemic area)	Salmonella bacteremia specifically linked to severe malaria
Very high parasitaemia >20%	Higher risk of bacteremia even in adults
Immunocompromised / HIV positive	Lower threshold for empirical antibiotics

When NOT to Add It

Patient responds well to artesunate within 24-48 hrs
Temperature settling with antipyretics
No signs of sepsis / shock
Blood culture negative or pending with low procalcitonin
Routine uncomplicated-to-moderate P. vivax - no indication

If You Do Decide to Add

Inj. Ceftriaxone 1g IV once daily (or 2g IV OD if pneumonia/meningitis suspected)

Duration: based on source - typically 5-7 days for pneumonia, 7-14 days for bacteremia
Cover is primarily for gram-negative enteric organisms (Salmonella, E. coli, Klebsiella)
If aspiration pneumonia: add Inj. Metronidazole 500 mg IV TDS for anaerobe cover

Practical Decision Rule

Severe P. vivax + adult
        ↓
Start artesunate. Send blood culture + CBC + procalcitonin.
        ↓
After 48 hrs:
  → Fever settling + culture negative → NO ceftriaxone needed
  → Fever persisting / shock / culture positive → ADD ceftriaxone

Bottom line: Do NOT add ceftriaxone empirically on day 1 for routine severe P. vivax in an adult. It is warranted only when there is a specific clinical trigger. Adding it unnecessarily risks antibiotic resistance, C. diff colitis, and drug costs without benefit.

(Harrison's Principles of Internal Medicine 22E, 2025)

This is a shared conversation. Sign in to Orris to start your own chat.